重藥控股(000950.SZ)半年度淨利潤升49.7%至4.63億元
格隆匯8月19日丨重藥控股(000950.SZ)發佈2019年半年度報告，實現營業收入162.06億元，同比增長33.80%；歸屬於上市公司股東的淨利潤4.63億元，同比增長49.70%；歸屬於上市公司股東的扣除非經常性損益的淨利潤4.31億元，同比增長45.63%；基本每股收益0.27元。
報告期內，公司有序推進近期併購項目的資源整合，積極輸出重慶醫藥的優勢資源及企業文化，優化各外省併購項目的管理層級配置，加強集約化發展和創新轉型，完善戰略產業佈局，區域協同發展初顯成效。
報告期內，公司全面貫徹落實年初各項工作計劃，積極應對各項困難和挑戰，大力推動企業高質量發展，取得了較好的成績。
1、“4+7”改革佔先機
2019年上半年，公司積極參與國家組織藥品集中採購試點方案(“4+7”)藥品配送工作，在入圍的25個帶量品種中，我司在重慶地區實現全覆蓋，同時在試點城市成都、西安，下屬商業公司也獲得部分品種配送權。
2、繼續探索渝新歐藥品進口全國總代理業務
公司利用重慶獲批藥品首次進口口岸和生物製劑檢驗口岸的時間及流程的相關優勢為契機，積極與各進口藥品生產廠家洽談全國總代理業務。
3、融資渠道多元化
報告期內，公司不斷與各金融機構溝通，創新融資業務，實現公司整體融資成本可控。公司開展了跨境融資、利率套期等項目，正在積極推進應收賬款無追索權保理、應收賬款資產證券化、超短期融資券等項目，保障了業務資金需求，拓展了融資渠道。
三方物流超預期、物流體系建設繼續有序進行
公司繼為阿斯利康提供西區分倉三方業務以來，輝瑞西區分倉也陸續上線運營，上半年完成三方業務收入共計620萬元。目前多家進口製藥廠商就與我司成立西部分倉提出合作意向，但目前我司現有物流倉儲承載能力已經飽和。
隨着公司銷售規模的增長及第三方醫藥物流暨西部分倉業務的市場需求，公司大力推進現代物流基地(二期)及四川、貴州、湖北、甘肅、寧夏等地的省級物流中心建設工程。爭取早日建設完成並開始運營，在完善公司中西部物流網絡的同時，成為進口品種藥品西區分倉的各個節點。
醫養健康板塊運營主體頤合健康公司在上半年完成管理團隊整合，通過管理人員科學化配置，實現了醫養健康板塊的降本增效；重鋼總醫院積極新開社區服務站，除基本診療服務外，為社區居民提供保健理療等增值服務；同時，重鋼總醫院抓緊各科室建設，全力推進三甲醫院創建工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
